Collection |

Cancer at Nature Research

The Nature Research editors who handle cancer primary research, methods, protocols and reviews bring you the latest articles, covering all aspects from disease mechanisms to therapeutic approaches. Collected here you will also find specially curated content, such as collections, focus issues and animations, all ready to be used in presentations and educational materials. You can also find out about the editors handling cancer contents, and the journals at Nature Research that publish articles on this topic and how to submit to them.

Sign up to the e-alert to receive highlights direct to your inbox.

Research Articles

  • Nature Communications | Article | open

    Acute myeloid leukaemia (AML) affects people of all ages. Here, the authors model AML in vivo and demonstrate that the age of the cell of origin impacts leukaemia development and the genetic signature where adult cells of origin give rise exclusively to AML and young cells of origin give rise to myeloid, lymphoid or mixed phenotype acute leukaemia.

    • Shahzya Chaudhury
    • , Caitríona O’Connor
    • , Ana Cañete
    • , Joana Bittencourt-Silvestre
    • , Evgenia Sarrou
    • , Áine Prendergast
    • , Jarny Choi
    • , Pamela Johnston
    • , Christine A. Wells
    • , Brenda Gibson
    •  &  Karen Keeshan
  • Nature Genetics | Letter

    Activating HER2 mutations are shown to confer resistance to ER-directed therapies in patients with ER+ metastatic breast cancer. Drug resistance caused by HER2 mutations was overcome by combining ER-directed therapy with a HER2 kinase inhibitor.

    • Utthara Nayar
    • , Ofir Cohen
    • , Christian Kapstad
    • , Michael S. Cuoco
    • , Adrienne G. Waks
    • , Seth A. Wander
    • , Corrie Painter
    • , Samuel Freeman
    • , Nicole S. Persky
    • , Lori Marini
    • , Karla Helvie
    • , Nelly Oliver
    • , Orit Rozenblatt-Rosen
    • , Cynthia X. Ma
    • , Aviv Regev
    • , Eric P. Winer
    • , Nancy U. Lin
    •  &  Nikhil Wagle
  • Nature Chemical Biology | Article

    ZCCHC4 was identified as a mammalian ribosome RNA (rRNA) N6-methyladenosine (m6A) writer protein that installs m6A 4220 in 28S rRNA. 28S rRNA methylation affects global translation and cell growth and contributes to tumorigenesis in cancer cells.

    • Honghui Ma
    • , Xiaoyun Wang
    • , Jiabin Cai
    • , Qing Dai
    • , S. Kundhavai Natchiar
    • , Ruitu Lv
    • , Kai Chen
    • , Zhike Lu
    • , Hao Chen
    • , Yujiang Geno Shi
    • , Fei Lan
    • , Jia Fan
    • , Bruno P. Klaholz
    • , Tao Pan
    • , Yang Shi
    •  &  Chuan He
  • Nature Immunology | Article

    Germinal center B cells undergo reiterative rounds of proliferation and selection. Melnick and colleagues show that the histone demethylase LSD1 is necessary for this reiterative process via its interactions with the transcription factor BCL6.

    • Katerina Hatzi
    • , Huimin Geng
    • , Ashley S. Doane
    • , Cem Meydan
    • , Reed LaRiviere
    • , Mariano Cardenas
    • , Cihangir Duy
    • , Hao Shen
    • , Maria Nieves Calvo Vidal
    • , Timour Baslan
    • , Helai P. Mohammad
    • , Ryan G. Kruger
    • , Rita Shaknovich
    • , Ann M. Haberman
    • , Giorgio Inghirami
    • , Scott W. Lowe
    •  &  Ari M. Melnick
  • Nature Medicine | Resource

    An integrated analysis of glioma samples from patients with neurofibromatosis 1 annotates their mutational, epigenetic, transcriptional, and immunological features and uncovers similitudes with a subset of sporadic gliomas.

    • Fulvio D’Angelo
    • , Michele Ceccarelli
    • , Tala
    • , Luciano Garofano
    • , Jing Zhang
    • , Véronique Frattini
    • , Francesca P. Caruso
    • , Genevieve Lewis
    • , Kristin D. Alfaro
    • , Luc Bauchet
    • , Giulia Berzero
    • , David Cachia
    • , Mario Cangiano
    • , Laurent Capelle
    • , John de Groot
    • , Francesco DiMeco
    • , François Ducray
    • , Walid Farah
    • , Gaetano Finocchiaro
    • , Stéphane Goutagny
    • , Carlos Kamiya-Matsuoka
    • , Cinzia Lavarino
    • , Hugues Loiseau
    • , Véronique Lorgis
    • , Carlo E. Marras
    • , Ian McCutcheon
    • , Do-Hyun Nam
    • , Susanna Ronchi
    • , Veronica Saletti
    • , Romuald Seizeur
    • , John Slopis
    • , Mariona Suñol
    • , Fanny Vandenbos
    • , Pascale Varlet
    • , Dominique Vidaud
    • , Colin Watts
    • , Viviane Tabar
    • , David E. Reuss
    • , Seung-Ki Kim
    • , David Meyronet
    • , Karima Mokhtari
    • , Hector Salvador
    • , Krishna P. Bhat
    • , Marica Eoli
    • , Marc Sanson
    • , Anna Lasorella
    •  &  Antonio Iavarone
  • Nature Communications | Article | open

    Cyclins A2 and E1 are known to regulate the cell cycle by promoting S phase entry and progression. Here, they identify an aggressive hepatocellular carcinoma subgroup exhibiting cyclin activation through various mechanisms and find this subgroup to display replication stress-induced structural rearrangements frequently activating TERT promoter.

    • Quentin Bayard
    • , Léa Meunier
    • , Camille Peneau
    • , Victor Renault
    • , Jayendra Shinde
    • , Jean-Charles Nault
    • , Iadh Mami
    • , Gabrielle Couchy
    • , Giuliana Amaddeo
    • , Emmanuel Tubacher
    • , Delphine Bacq
    • , Vincent Meyer
    • , Tiziana La Bella
    • , Audrey Debaillon-Vesque
    • , Paulette Bioulac-Sage
    • , Olivier Seror
    • , Jean-Frédéric Blanc
    • , Julien Calderaro
    • , Jean-François Deleuze
    • , Sandrine Imbeaud
    • , Jessica Zucman-Rossi
    •  &  Eric Letouzé

Reviews

  • Nature Reviews Urology | Year in Review

    The treatment of metastatic kidney cancer is rapidly evolving with the shift from immune checkpoint inhibitor monotherapy to combination therapy. In 2018, the combination of nivolumab–ipilimumab received regulatory approval and multiple positive clinical trials were reported with combinations of PD-1 or PD-L1 inhibitors in conjunction with antiangiogenic drugs.

    • Chung-Han Lee
    •  &  Robert J. Motzer
  • Nature Reviews Clinical Oncology | Year in Review

    In 2018, advances in the treatment of non-small-cell lung cancer (NSCLC) have been observed both in trials of immunotherapies and targeted agents, leading to dramatically improved options for patients with metastatic and stage III NSCLC.

    • Jennifer W. Carlisle
    •  &  Suresh S. Ramalingam
  • Nature Reviews Clinical Oncology | Year in Review

    In 2018, the results of multiple phase III trials in metastatic renal cell carcinoma (mRCC) were presented. A phase III noninferiority trial demonstrated the importance of careful patient selection before cytoreductive nephrectomy. Additionally, three randomized phase III trials demonstrated the superiority of combination therapy with an immune-checkpoint inhibitor backbone versus sunitinib in patients with treatment-naive mRCC.

    • Moshe C. Ornstein
    •  &  Brian I. Rini
  • Nature Reviews Cancer | Review Article

    This Review discusses causal germline variants in prostate cancer identified through genome-wide association studies (GWAS) and post-GWAS analyses. The latter are vital to identify causal variants and molecular mechanisms by which these variants promote prostate tumorigenesis, with potential clinical applications.

    • Samaneh Farashi
    • , Thomas Kryza
    • , Judith Clements
    •  &  Jyotsna Batra
  • Nature Reviews Cancer | Review Article

    In this Review, Altorki et al. discuss how the tumour-reprogrammed lung microenvironment can contribute to primary lung tumour progression as well as lung metastasis from extrapulmonary neoplasms by promoting inflammation, angiogenesis, immune modulation and therapeutic responses.

    • Nasser K. Altorki
    • , Geoffrey J. Markowitz
    • , Dingcheng Gao
    • , Jeffrey L. Port
    • , Ashish Saxena
    • , Brendon Stiles
    • , Timothy McGraw
    •  &  Vivek Mittal
  • Nature Reviews Clinical Oncology | Review Article

    The mechanisms of resistance to immunotherapy seem to broadly overlap with the immunoediting process whereby cancers evade detection by the immune system. The authors of this Review discuss these interactions as well as the strategies that can be used to overcome therapeutic resistance

    • Jake S. O’Donnell
    • , Michele W. L. Teng
    •  &  Mark J. Smyth

News & Commentary

  • Nature Reviews Cancer | Research Highlight

    New findings published in Nature Medicine highlight a role for the anti-CTLA4 antibody ipilimumab when combined with radiotherapy in treating metastatic NSCLC.

    • Jordan Hindson
  • Nature Biomedical Engineering | News & Views

    A humanized biomaterial microenvironment that mimics the pre-metastatic niche captures disseminated tumour cells and recapitulates metastatic progression after implantation in xenografted mice.

    • Irina Matei
    • , Sham Rampersaud
    •  &  David Lyden
  • Nature Reviews Cancer | Editorial

    Cancer research and Nature Reviews Cancer have both experienced many highs and lows in 2018, and we look forward to what 2019 has in store.

    • Sarah Seton-Rogers